AU2009222998B2 - Anti-TYRP1 antibodies - Google Patents

Anti-TYRP1 antibodies Download PDF

Info

Publication number
AU2009222998B2
AU2009222998B2 AU2009222998A AU2009222998A AU2009222998B2 AU 2009222998 B2 AU2009222998 B2 AU 2009222998B2 AU 2009222998 A AU2009222998 A AU 2009222998A AU 2009222998 A AU2009222998 A AU 2009222998A AU 2009222998 B2 AU2009222998 B2 AU 2009222998B2
Authority
AU
Australia
Prior art keywords
ser
val
thr
leu
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009222998A
Other languages
English (en)
Other versions
AU2009222998A1 (en
Inventor
Paul J. Balderes
Xiaoqiang Kang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImClone LLC
Original Assignee
ImClone LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40790741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009222998(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ImClone LLC filed Critical ImClone LLC
Publication of AU2009222998A1 publication Critical patent/AU2009222998A1/en
Application granted granted Critical
Publication of AU2009222998B2 publication Critical patent/AU2009222998B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053Skin, nerves, brain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2009222998A 2008-03-12 2009-03-11 Anti-TYRP1 antibodies Ceased AU2009222998B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6919908P 2008-03-12 2008-03-12
US61/069,199 2008-03-12
PCT/US2009/036739 WO2009114585A1 (en) 2008-03-12 2009-03-11 Anti-tyrp1 antibodies

Publications (2)

Publication Number Publication Date
AU2009222998A1 AU2009222998A1 (en) 2009-09-17
AU2009222998B2 true AU2009222998B2 (en) 2013-05-23

Family

ID=40790741

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009222998A Ceased AU2009222998B2 (en) 2008-03-12 2009-03-11 Anti-TYRP1 antibodies

Country Status (19)

Country Link
US (1) US7951370B2 (enExample)
EP (1) EP2268672A1 (enExample)
JP (1) JP2011516041A (enExample)
KR (1) KR101203777B1 (enExample)
CN (1) CN101970500B (enExample)
AR (1) AR070821A1 (enExample)
AU (1) AU2009222998B2 (enExample)
BR (1) BRPI0909633A2 (enExample)
CA (1) CA2718289A1 (enExample)
CL (1) CL2009000567A1 (enExample)
EA (1) EA019517B1 (enExample)
IL (1) IL207581A0 (enExample)
MX (1) MX2010010021A (enExample)
NZ (1) NZ587305A (enExample)
PE (1) PE20091679A1 (enExample)
TW (1) TWI384997B (enExample)
UA (1) UA99339C2 (enExample)
WO (1) WO2009114585A1 (enExample)
ZA (1) ZA201006099B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2167540B1 (en) * 2007-06-29 2018-02-14 F. Hoffmann-La Roche AG Heavy chain mutant leading to improved immunoglobulin production
MX2016010177A (es) 2014-02-07 2017-01-09 Dong Wha Pharm Co Ltd Composicion adyuvante anticancerosa que contiene promotor de la expresion de rip3 como principio activo, metodo para la deteccion de adyuvante anticanceroso que potencia la sensibilidad al farmaco anticanceroso mediante la estimulacion de la expresion de rip3 y metodo para controlar la sensibilidad del farmaco anticanceroso.
DK3233907T3 (da) 2014-12-19 2021-06-07 Genmab As Bispecifikke heterodimeriske proteiner hos gnavere
RU2630647C1 (ru) * 2016-05-27 2017-09-11 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
GB201613167D0 (en) 2016-07-29 2016-09-14 Univ Southampton Cancer and b-cell related disease therapy
WO2018075586A1 (en) * 2016-10-18 2018-04-26 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof
MX2019015053A (es) * 2017-06-14 2020-02-13 Adicet Bio Inc Anticuerpos capaces de unirse a hla-a2/tyrd de forma restringida por hla y usos de estos.
RU2687609C1 (ru) * 2018-05-30 2019-05-15 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Гуманизированное антитело к конформационному эпитопу сз компонента комплемента человека
EP3856775B9 (en) 2018-09-27 2025-01-22 Autolus Limited Chimeric antigen receptor
EP3876988A4 (en) * 2018-11-09 2022-11-09 Beth Israel Deaconess Medical Center THERAPIES TARGETED AGAINST CDCP1
TWI881476B (zh) * 2018-12-21 2025-04-21 瑞士商赫孚孟拉羅股份公司 結合cd3之抗體
CN114765980A (zh) * 2019-09-06 2022-07-19 加利福尼亚大学董事会 用于治疗癌症的嵌合抗原受体及相关方法和组合物
WO2023094569A1 (en) * 2021-11-26 2023-06-01 F. Hoffmann-La Roche Ag Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies
WO2025104289A1 (en) 2023-11-17 2025-05-22 Medincell S.A. Antineoplastic combinations
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4798790A (en) 1985-07-18 1989-01-17 Sloan-Kettering Institute Monoclonal antibody specific for a pigmentation associated antigen
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
EP0362371A4 (en) 1988-04-15 1990-10-24 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
ATE119198T1 (de) 1988-04-16 1995-03-15 Celltech Ltd Verfahren zur herstellung von proteinen mittels rekombinanter dna.
IE910820A1 (en) 1990-03-22 1991-09-25 Sloan Kettering Inst Cancer Gp75 as a tumor vaccine for melanoma
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
AU6171196A (en) * 1995-06-07 1996-12-30 Sloan-Kettering Institute For Cancer Research Therapeutic uses of ta99
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
BR9815289A (pt) * 1997-11-14 2001-12-26 Euro Celtique Sa Imunoglobulina modificada, molécula, ácidonucleico isolado, célula contendo o mesmo, animalnão-humano recombinante, composiçãofarmacêutica, composição de vacina, processospara identificar ou medir ou detectar um antìgenode câncer, um antìgeno de um agente de doençainfecciosa, um ligante, e um receptor em umaamostra a ser testada, kits para detecção de umantìgeno de câncer, de um antìgeno de um agentede doença infecciosa, de um receptor celular paraum agente de doença infecciosa, de um ligante, e deum antìgeno de câncer, processos de diagnósticoou de exame para a presença de ou umapredisposição para desenvolvimento de um câncertipificado pela presença aumentada de umantìgeno de câncer, e para a presença de umagente de doença infecciosa, processos detratamento ou de prevenção de um câncertipificado pela presença de um antìgeno de câncer,de uma doença infecciosa tipificada pela presençade um antìgeno de agente de doença infecciosa, ede uma doença causada por um agente de doençainfecciosa que se liga em um receptor celular,processos para modulação de atividade de umprimeiro membro de um par de ligação, processo deprodução de uma imunoglobulina modificada,processo de produção de um ácido nucleicocodificador de imunoglobulina modificada, e, ácidonucleico isolado
NZ522847A (en) * 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
WO2006047340A2 (en) * 2004-10-22 2006-05-04 Amgen Inc. Methods for refolding of recombinant antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATEL DIPA ET AL: "Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1" I-;lUMAN ANTIBODIES, AMSTERDAM, NL, vol. 16, no. 3-4, 1 January 2007 (2007-01-01), pages 127-136. *

Also Published As

Publication number Publication date
CL2009000567A1 (es) 2010-02-26
KR20100113631A (ko) 2010-10-21
UA99339C2 (ru) 2012-08-10
CN101970500A (zh) 2011-02-09
TWI384997B (zh) 2013-02-11
KR101203777B1 (ko) 2012-11-21
AR070821A1 (es) 2010-05-05
NZ587305A (en) 2012-05-25
EA019517B1 (ru) 2014-04-30
EP2268672A1 (en) 2011-01-05
AU2009222998A1 (en) 2009-09-17
IL207581A0 (en) 2010-12-30
MX2010010021A (es) 2011-02-15
US7951370B2 (en) 2011-05-31
CN101970500B (zh) 2013-08-14
US20090232823A1 (en) 2009-09-17
JP2011516041A (ja) 2011-05-26
CA2718289A1 (en) 2009-09-17
EA201071068A1 (ru) 2011-04-29
BRPI0909633A2 (pt) 2015-09-22
PE20091679A1 (es) 2009-11-04
WO2009114585A1 (en) 2009-09-17
TW200944232A (en) 2009-11-01
ZA201006099B (en) 2012-01-25

Similar Documents

Publication Publication Date Title
AU2009222998B2 (en) Anti-TYRP1 antibodies
CN112175081B (zh) 抗cd137分子及其用途
CN109476746B (zh) Egfr结合分子
ES2686335T3 (es) Nuevos anticuerpos que inhiben la dimerización de c-Met y sus utilizaciones
AU2009260517B2 (en) Anti-FLT3 antibodies
ES2616355T3 (es) Anticuerpos para el receptor humano de muerte programada PD-1
AU2015273532B2 (en) Antibodies directed against CD127
CN107074953A (zh) 人源化抗ox40抗体及其用途
KR102452349B1 (ko) Ceacam1에 대한 인간화 항체
KR20240017912A (ko) 항-ccr8 항체 및 이의 용도
KR102819051B1 (ko) Il7 수용체 세포외 도메인의 알파 쇄에 대해 지시된 비-길항성 항체 및 암 치료에 있어서 이의 용도
CN107708666A (zh) 治疗癌症的联合疗法
CN113166242A (zh) 用于癌症的组合疗法
AU2020316498A1 (en) Humanized anti-VEGF monoclonal antibody
KR20100110852A (ko) 개량형 인간화 항-인간 α9 인테그린 항체
WO2023030311A1 (zh) 靶向Siglec15的抗原结合蛋白及其用途
HK40089230A (zh) 药物组合物及用途
HK40057716A (en) Combination therapy for cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired